Latest News & Features
article
The pharmaceutical industry has continued to shift towards biologic-based drugs. Protecting the underlying technology continues to be a priority for companies and, indeed, patents covering these antibody drugs are worth billions of dollars. However, as the science and case law in this area have evolved, biopharmaceutical companies now face even higher hurdles on the road to the effective protection of their innovations. 3 September 2020
article
The pharmaceutical industry has continued to shift towards biologic-based drugs. Protecting the underlying technology continues to be a priority for companies and, indeed, patents covering these antibody drugs are worth billions of dollars. However, as the science and case law in this area have evolved, biopharmaceutical companies now face even higher hurdles on the road to the effective protection of their innovations. 3 September 2020
Big Pharma
Gilead Sciences has unveiled an agreement with Jounce Therapeutics to exclusively develop and license its antibody programme, JTX-1811, which is designed to fight cancer cells. 2 September 2020
Americas
Gilead Sciences division Kite Pharma wants a federal appeals court to reverse a $1.2 billion patent award in favour of Juno Pharmaceuticals and a cancer research institute. 2 September 2020
Americas
Anacor Pharmaceuticals has unsuccessfully challenged the invalidation of four patents covering Kerydin, an antifungal treatment for nails. 1 September 2020
Big Pharma
The European Commission’s first ever contract to secure a COVID-19 vaccine came into force on August 27, after it signed a deal with pharmaceutical company AstraZeneca. 1 September 2020
Asia
As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain. 1 September 2020
Big Pharma
Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta. 28 August 2020
Americas
Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors. 27 August 2020
article
The current pandemic has thrown the spotlight more brightly than ever on the need for collaboration between research institutes and industry. 27 August 2020